Market Research Reports and Industry Reports

Therapeutic Class Report Overview - Future Of GPR Agonist

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Despite about half a dozen distinct targets having been innovated and introduced in the market for the oral treatment of Type 2 diabetes, ~60% of diabetics still exhibit progressive worsening of glycemic control and ~half of them end up with daily insulin. Increasing epidemiology of Type 2 diabetes due to genetic/lifestyle changes, as well as micro/macrovascular (CV) complication associated with diabetes, demands the researcher to find newer options for treating diabetes which can address other consequences along with HbA1c reduction. Selective PPAR agonists, DGAT1 (diglyceride Acyltransferase 1) inhibitors, GPR (G-protein receptor) agonist, Glucokinase inhibitors are some of the early targets which are in clinical development and have the potential to come into the clinic in the next decade.

Amongst these novel targets, a few candidates from GPR (G-protein couple receptors) agonist are nearing late stage development. Ability to directly modulate insulin and GLP-1 secretion in glucose depended manner is the key trait of this class. Through this, GPR agonist controls hyperglycemia without hypoglycemia, and provides weight loss advantage. Recent publications suggest GPR agonist have complementary action with DPP-IV inhibitors. This report discuss in details about the merits/demerits of developing GPR agonist, pipeline GPR agonist together with sales estimate of key pipeline candidate through 2020 across the world.
N/A

List Of Tables

N/A

List Of Figures

N/A

2017 US Therapeutic Drug Monitoring (TDM) Market: Future Horizons and Growth Strategies--Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities

This new 249-page report from VPGMarketResearch.com provides a comprehensive analysis of the US therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of

USD 3500View Report

2017 UK Therapeutic Drug Monitoring (TDM) Market: Future Horizons and Growth Strategies--Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities

This new 247-page report from VPGMarketResearch.com provides a comprehensive analysis of the UK therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of

USD 2450View Report

2017 Spain Therapeutic Drug Monitoring (TDM) Market: Future Horizons and Growth Strategies--Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities

This new 249-page report from VPGMarketResearch.com provides a comprehensive analysis of the Spanish therapeutic drug monitoring market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of

USD 2450View Report

Therapeutic Class Report Overview : Hepatitis C Virus Infection

The launch of Protease inhibitors (PIs) created a wave in 2011-12 and accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations

USD 1000View Report

Therapeutic Class Report Overview - Japan Biosimilars

200b worth of biologic products is going off patent by 2015 and this value exceeds ~ 500b if we include products that will see their patent expiries by 2021 in

USD 1000View Report

Therapeutic Class Report Overview - Hemophilia

Hemophilia is an inherited (X-linked recessive trait), lifelong bleeding disorder that prevents blood from clotting due to insufficient or lack of adequate amount of clotting factors Factor VIII (FVIII)

USD 2000View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 1000
  • Site Licence    $ 2000
  • Enterprisewide Licence    $ 3000
$ 1000

Reports Details

Published Date : Feb 2013
No. of Pages :20
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube